Context
Voluntis is a digital therapeutics pioneer that empowers people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes.
A portfolio of solutions targeting the world’s top two therapy areas: diabetes and cancer.
Partnerships with leading players in their respective fields: Sanofi, AstraZeneca, Roche, Google.
Vast program of clinical trials, with 5 successfully completed and 2 in progress.
Commercial launch underway for Diabeo® and Insulia® (therapeutic solutions for diabetes) in Europe and the US.
First payer contract announced with WelldyneRx.
120 employees located in Paris and Boston.
Use of proceeds includes the scale-up of commercial activities in North America and Europe and the development of the company’s proprietary multi-cancer solution.
About Voluntis
Voluntis creates digital companions that empower people to self-manage their treatment in remote collaboration with their health care teams. Dedicated to chronic conditions, Voluntis’ products aim to personalize treatment, support team-care coordination and improve real-world outcomes. Voluntis leverages its expertise in digitizing clinical algorithms and its technology platform to design its companion solutions. These include Insulia and Diabeo in diabetes as well as eCO and Zemy in oncology. Voluntis has long-standing partnerships with leading life science companies such as Sanofi, Roche and AstraZeneca. It is a founding member of the Digital Therapeutics Alliance.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for Voluntis’ IPO, the first ever listing of a digital therapeutics company raising EUR30.1 million
Bryan, Garnier & Co acted as Joint Global Coordinator and Joint Bookrunner.
First digital therapeutics IPO globally and first healthcare IPO on Euronext in 2018.
EUR30.1 million raised in gross proceeds.
IPO anchored by tier-1 leading international healthcare investors including Sanofi Ventures.
Geographically diverse institutional demand with France representing only 18%.
Voluntis’ IPO is the 10th healthcare transaction closed by Bryan, Garnier & Co in 2018, following Celyad’s successful EUR46.1 million placement and Medigene’s EUR48.3 million equity offering.
Market cap at IPO: EUR105.9 million.
Share